tetano
Editor, Senior Moderator
J Clin Med
. 2021 Apr 19;10(8):1771.
doi: 10.3390/jcm10081771.
Seroprevalence of Antibodies against SARS-CoV-2 in Children with Juvenile Idiopathic Arthritis a Case-Control Study
Violetta Opoka-Winiarska[SUP] 1 [/SUP], Ewelina Grywalska[SUP] 2 [/SUP], Izabela Korona-Glowniak[SUP] 3 [/SUP], Katarzyna Matuska[SUP] 4 [/SUP], Anna Malm[SUP] 3 [/SUP], Jacek Roli?ski[SUP] 2 [/SUP]
Affiliations
Abstract
There is limited data on the effect of the novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) on pediatric rheumatology. We examined the prevalence of antibodies against SARS-CoV-2 in children with juvenile idiopathic arthritis (JIA) and a negative history of COVID-19 and the correlation of the presence of these antibodies with disease activity measured by juvenile arthritis disease activity score (JADAS). In total, 62 patients diagnosed with JIA, under treatment with various antirheumatic drugs, and 32 healthy children (control group) were included. Serum samples were analyzed for inflammatory markers and antibodies and their state evaluated with the juvenile arthritis disease activity score (JADAS). JIA patients do not have a higher seroprevalence of anti-SARS-CoV-2 antibodies than healthy subjects. We found anti-SARS-CoV-2 antibodies in JIA patients who did not have a history of COVID-19. The study showed no unequivocal correlation between the presence of SARS-CoV-2 antibodies and JIA activity; therefore, this relationship requires further observation. We also identified a possible link between patients' humoral immune response and disease-modifying antirheumatic treatment, which will be confirmed in follow-up studies.
Keywords: COVID-19; SARS-CoV-2; disease-modifying antirheumatic drugs; juvenile idiopathic arthritis.
. 2021 Apr 19;10(8):1771.
doi: 10.3390/jcm10081771.
Seroprevalence of Antibodies against SARS-CoV-2 in Children with Juvenile Idiopathic Arthritis a Case-Control Study
Violetta Opoka-Winiarska[SUP] 1 [/SUP], Ewelina Grywalska[SUP] 2 [/SUP], Izabela Korona-Glowniak[SUP] 3 [/SUP], Katarzyna Matuska[SUP] 4 [/SUP], Anna Malm[SUP] 3 [/SUP], Jacek Roli?ski[SUP] 2 [/SUP]
Affiliations
- PMID: 33921679
- DOI: 10.3390/jcm10081771
Abstract
There is limited data on the effect of the novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) on pediatric rheumatology. We examined the prevalence of antibodies against SARS-CoV-2 in children with juvenile idiopathic arthritis (JIA) and a negative history of COVID-19 and the correlation of the presence of these antibodies with disease activity measured by juvenile arthritis disease activity score (JADAS). In total, 62 patients diagnosed with JIA, under treatment with various antirheumatic drugs, and 32 healthy children (control group) were included. Serum samples were analyzed for inflammatory markers and antibodies and their state evaluated with the juvenile arthritis disease activity score (JADAS). JIA patients do not have a higher seroprevalence of anti-SARS-CoV-2 antibodies than healthy subjects. We found anti-SARS-CoV-2 antibodies in JIA patients who did not have a history of COVID-19. The study showed no unequivocal correlation between the presence of SARS-CoV-2 antibodies and JIA activity; therefore, this relationship requires further observation. We also identified a possible link between patients' humoral immune response and disease-modifying antirheumatic treatment, which will be confirmed in follow-up studies.
Keywords: COVID-19; SARS-CoV-2; disease-modifying antirheumatic drugs; juvenile idiopathic arthritis.